Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Completed · Phase 2

Conditions studied: Carcinoma, Renal Cell

In brief

The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.

Key facts

Study ID

NCT00256880

Run by

GlaxoSmithKline

People needed

100

Starts

2005-01-01

Expected to finish

2005-12-01

Last updated by the study team

2017-01-18

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have diagnosis of relapsed or refractory multiple.
• bone marrow function [ANC (absolute neutrophil count) greater than 1000/mm3]; platelet count greater than or equal to 75,000/mm3.
• renal function (calculated creatinine clearance >50 mL.min, albumin less than or equal to 500 mg).

You may not qualify if…

• Failed more than 3 prior lines of therapy including stem cell transplant.
• Females who are pregnant or nursing.
• Unstable blood pressure.
• Significant heart conditions or history of thrombosis.
• Any unstable, pre-existing major medical condition or history of other cancers.
• Have received an investigational drug, chemotherapy, radiation treatment or surgery within 28 days prior to entering the study.

Where it is running

• GSK Investigational Site — Little Rock, Arkansas, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Durham, North Carolina, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Seattle, Washington, United States
• GSK Investigational Site — East Melbourne, Victoria, Australia
• GSK Investigational Site — Melbourne, Victoria, Australia
• GSK Investigational Site — Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.